BACKGROUND Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome
Risk stratification tools are well validated and guideline recommended for use in ACS to assist with short-term prognostication and shortterm therapeutic decision making (e.g., early invasive strategy) (4) (5) (6) (7) (8) (9) . However, there are fewer tools available to assist with decisions on long-term response to treatment in patients in the stable phase of ischemic heart disease (IHD), such as patients whose conditions are stabilized after ACS or who have established IHD without known previous myocardial infarction (MI) (10, 11) .
We recently developed a simple 9-point risk stratification tool to predict recurrent CV events in a large population of stable patients with previous MI from the TRA 2 P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis In Myocardial Infarction 50) trial (11) (12) (13) . The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2 P) incorporates the following readily available clinical characteristics: older age, diabetes, hypertension, smoking, peripheral artery disease, previous stroke, previous coronary artery bypass graft (CABG), history of heart failure, and renal dysfunction (Central Illustration). In addition to predicting long-term outcomes, the TRS 2 P identified high-risk patients who experienced the greatest absolute benefit from intensive secondary preventive therapy with vorapaxar, an antiplatelet agent that inhibits thrombin-mediated activation of platelets through the protease activated receptor (PAR)-1 (11) .
In the present analysis, we tested the hypothesis that the TRS 2 P would effectively identify a post-ACS population of patients at higher risk for recurrent CV events who have the greatest potential for benefit from the addition of ezetimibe to statin therapy in the IMPROVE-IT trial. 
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Baseline characteristics were well matched between the placebo and simvastatin treatment group (n ¼ 8,869) and the ezetimibe and simvastatin treatment group (n ¼ 8,848) (p > 0.05 for all variables in Table 1 ). The median follow-up was 6.0 years (quartiles: 4.3; 7.1 years).
APPLICATION OF THE TIMI RISK SCORE FOR SECONDARY
PREVENTION. Each of the 9 clinical variables in the TRS 2 P were independent predictors of CV death, MI, or ischemic stroke in the control (placebo and simvastatin) treatment group (p < 0.001 for each) (Online Table 1 ). The mean number of risk indicators for each patient was 1.8 AE 1.2 in both treatment arms.
Risk Stratification and Ezetimibe in the IMPROVE-IT Trial
The TRS 2 P showed a strong graded relationship with the rate of CV death, MI, or ischemic stroke at 7 years in the control (placebo and simvastatin) group that ranged from 8.6% for patients with 0 risk indicators to 68.4% for patients with $5 risk indicators (p trend <0.0001) (Figure 1) . A similar, significant pattern of increasing event rates with an increasing number of risk indicators was observed for the prespecified primary (Online Figure 1) and secondary IMPROVE-IT endpoints, as well as for individual Figure 3A , Online Table 2 ).
A similar pattern of increasing benefit was observed across risk categories for the IMPROVE-IT pre-specified primary and secondary trial endpoints, as well as for most of the individual, nonfatal endpoints ( Figures 3B to 3D , Online Table 2 is the chi-square test for trend.
any risk group with the addition of ezetimibe (Online Table 2 ). Table 3 .
DISCUSSION
Ezetimibe has been shown to improve CV outcomes when it is added to statin therapy in patients stabilized after ACS (1). We sought to determine whether we could identify higher-risk populations of patients who have the greatest potential for benefit from the addition of ezetimibe to statin therapy by using the TRS 2 P, a simple 9-point risk stratification tool (11) . In this secondary analysis, we found that in patients who conditions were stabilized after ACS in IMPROVE-IT, the TRS 2 P identified the following: 1) a strong gradient of risk for recurrent CV events; and, importantly; 2) an increasingly favorable relative and absolute benefit from the addition of ezetimibe to simvastatin therapy with increasing risk profile.
TREATMENT BENEFIT WITH THE ADDITION OF EZETIMIBE TO STATIN THERAPY. The TRS 2 P identified differential treatment benefit for the addition of ezetimibe to simvastatin therapy when patients at higher risk for recurrent CV events experienced the greatest relative and absolute risk reductions. In this analysis, the TRS 2 P identified differential risk for long-term recurrent CV events in IMPROVE-IT, an early post-ACS population of patients, with a 3-to 4-fold gradient for MI or ischemic stroke and a 7-fold gradient for CV death across low-, medium-, and high-risk categories over 7 years. Despite the pragmatic approach to risk stratification, the TRS 2 P demonstrated reasonable discrimination and good calibration for long-term outcomes in post-ACS patients. Moreover, our findings demonstrate a practical approach to personalizing secondary preventive therapy on the basis of patients' risk.
STUDY LIMITATIONS. The TRS 2 P was designed to be a simple tool, using readily available clinical data.
There are other previously identified risk indicators (e.g., abnormal imaging and angiography) and other yet to be identified parameters (e.g., biochemical or genetic characteristics) that may provide additional refinement for stratification. However, the ability of this simple scoring system to identify differential treatment benefit for different classes of secondary preventive therapy supports its clinical utility. Our data are derived from a population of patients who met specific trial inclusion criteria and agreed to participate in a clinical trial, and this may influence generalizability to the general population. For example, low-risk patients, as defined by the TRS criteria with higher baseline LDL-C than those who were enrolled in IMPROVE-IT (>100 mg/dl during statin therapy or >125 mg/dl in the absence of lipidlowering therapy), may derive benefit from the addition of ezetimibe to statin therapy. Furthermore, the generalizability of this approach to other lipidlowering therapy, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, will need to be evaluated. Finally, the IMPROVE-IT trial evaluated a strategy of the addition of ezetimibe to a moderate-to high-intensity statin (simvastatin 40 to 80 mg) versus moderate-to high-intensity statin alone to achieve on-treatment LDL-C levels of 48 to 51 mg/dl and 66 to 68 mg/dl, respectively. The additive, proportionate reduction in LDL-C when ezetimibe was combined with a statin in this study was similar to that seen in other studies regardless of the background dose (or type) of statin (23, 24) . Therefore, although it is not possible specifically to address the CV benefit of the addition of ezetimibe to a highintensity statin (e.g., atorvastatin 80 mg daily)
because it was not studied in IMPROVE-IT, it could be hypothesized that the magnitude of benefit for the addition of ezetimibe would be more related to the baseline LDL-C (and therefore the absolute reduction in LDL-C on the basis of a consistent, proportionate reduction in LDL-C with ezetimibe on top of statin therapy), than to the intensity of statin dosing (1, 25) .
CONCLUSIONS
Atherothrombotic risk stratification using the TRS 2 P may help clinicians with therapeutic decisions regarding the addition of ezetimibe to statin therapy for secondary prevention after ACS.
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